A public-private partnership for the estimation of brand-specific COVID-19 vaccine effectiveness in Europe
What is COVIDRIVE?
COVIDRIVE is a public-private partnership launched in 2020 to address the joint need to monitor COVID-19 vaccination programmes for public health institutes in Europe and to assess brand-specific COVID-19 vaccine effectiveness (CVE) for the companies as part of their regulatory obligations. To tackle the COVID-19 public health crisis, the European Medicines Agency (EMA) has recommended to make use of existing efforts and encourage a common approach to assess COVID-19 vaccines in real life settings.
COVIDRIVE will perform brand-specific studies through a multi-stakeholder’s public-private European collaborative platform. First COVID-19 vaccine effectiveness study is set to start in July 2021.
COVIDRIVE is leveraging an existing vaccine effectiveness platform (DRIVE) which provides yearly brand-specific influenza vaccine effectiveness (IVE) estimates to the EMA.
COVIDRIVE consortium is open to new partners (public health institutes, pharmaceutical companies, small-medium enterprises, academia…) and new study sites to be part of our European-wide network.
VISION AND MISSION
JOINING FORCES TOWARDS A BETTER UNDERSTANDING OF VACCINES AND PREVENTION OF INFECTIOUS DISEASES
The partnership intends to conduct multiple COVID-19 vaccine effectiveness (CVE) studies which fall under the following scope:
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana
Excellence in pharmacovigilance and Epidemiology
Finnish Institute for Health and Welfare